Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treatment options for acromegaly

M C Sheppard1, P M Stewart

  • 1Department of Medicine, University of Birmingham, England.

Metabolism: Clinical and Experimental
|August 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oral 11β-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trial.

European journal of endocrinology·2022
Same author

Acromegaly.

QJM : monthly journal of the Association of Physicians·2016
Same author

Tissue specific regulation of glucocorticoids in severe obesity and the response to significant weight loss following bariatric surgery (BARICORT).

The Journal of clinical endocrinology and metabolism·2015
Same author

Central hypoadrenalism.

The Journal of clinical endocrinology and metabolism·2014
Same author

Expression of 11β-hydroxysteroid dehydrogenase type 1 in the human hypothalamus.

Journal of neuroendocrinology·2013
Same author

Short- and long-term glucocorticoid treatment enhances insulin signalling in human subcutaneous adipose tissue.

Nutrition & diabetes·2012
Same journal

Ablation of microglial estrogen receptor alpha predisposes male mice to diet-induced obesity.

Metabolism: clinical and experimental·2026
Same journal

Pathophysiology-based subtypes of individuals at high-risk of type 2 diabetes: multi-omics profiles and lifestyle differences across subtypes.

Metabolism: clinical and experimental·2026
Same journal

A thermosensitive TET-Parkin epigenetic axis couples mitochondrial quality control to adaptive thermogenesis in adipose tissue.

Metabolism: clinical and experimental·2026
Same journal

Raffinose targets the NQO1/NF-κB axis to attenuate DON-driven microglial activation and neuroinflammation via metabolic reprogramming.

Metabolism: clinical and experimental·2026
Same journal

Endothelial NPR-C promotes insulin resistance via Caveolin-1-mediated insulin transcytosis.

Metabolism: clinical and experimental·2026
Same journal

Macrophage-enriched GPR91 aggravates acute liver injury by inhibiting efferocytosis via the AC/cAMP/PPARγ pathway.

Metabolism: clinical and experimental·2026
See all related articles

Long-acting injectable Sandostatin-LAR effectively reduced growth hormone (GH) and normalized insulin-like growth factor-1 (IGF-1) in acromegaly patients. This treatment improved symptoms without increasing adverse events compared to subcutaneous administration.

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • Acromegaly, characterized by excess growth hormone (GH), poses treatment challenges with surgery and radiotherapy having limitations.
  • Evaluating treatment efficacy for acromegaly is difficult due to a lack of consensus on defining a cure.
  • Persistent GH hypersecretion and delayed effects of radiotherapy necessitate interest in pharmacological interventions.

Purpose of the Study:

  • To evaluate the efficacy and safety of Sandostatin-LAR in managing acromegaly.
  • To assess the impact of Sandostatin-LAR on GH and IGF-1 levels, as well as clinical symptoms.

Main Methods:

  • Eight patients with biochemically diagnosed acromegaly (GH non-suppression post-glucose tolerance test) were treated.
  • Sandostatin-LAR was administered intramuscularly at doses of 20-30 mg every 4 weeks.

Related Experiment Videos

  • Serum octreotide, GH, and IGF-1 levels were monitored, along with clinical signs and symptoms.

    • Main Results:

    • Intramuscular Sandostatin-LAR achieved consistent therapeutic octreotide levels.
    • GH secretion was suppressed to ≤ 5 µg/L in all patients.
    • IGF-1 levels were lowered in all patients, with normalization in seven out of eight.
    • Clinical symptoms and signs of acromegaly improved or resolved.
    • No increase in adverse events was observed compared to subcutaneous treatment.

    Conclusions:

    • Intramuscular Sandostatin-LAR is an effective and well-tolerated treatment for acromegaly.
    • This formulation offers a viable pharmacological option for managing GH excess and its associated symptoms.
    • Sandostatin-LAR provides a consistent and therapeutic approach to acromegaly management.